Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study

Overview of attention for article published in Journal of Clinical Oncology, April 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

blogs: 1 blog
twitter: 30 X users

wikipedia: 1 Wikipedia page
reddit: 1 Redditor

Readers on

mendeley: 32 Mendeley

So far, Altmetric has seen 31 X posts from 30 X users, with an upper bound of 116,270 followers.

低腫瘍量の濾胞性リンパ腫へのRit皮下投与を用いた短期維持治療ランダム化試験 (LYSA study) ・4年PFS 58.1% vs 41.2%、CR率 59% vs 36.3%で有意に皮下投与/短期維持療法群で優れた。・最初3か月のRit high AUCは独立したCR,PFS,TTNTの予後良好因子だった。 https://t.co/…

RT @DrRaulCordoba: #Hematology Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burde…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 27 additional X posts.